ClinicalTrials.gg
Active, not recruitingNCT02910414TARGET BP IUpdated Oct 3, 2023

TARGET BP I Clinical Trial

A Phase 3 interventional study of Dehydrated alcohol and Peregrine System Kit (Sham Procedure) in Hypertension, sponsored by Ablative Solutions, Inc.. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-10-03.

Sponsored by Ablative Solutions, Inc. · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2023, 2 years 11 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
300
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 2,031 studies in Hypertension with a site in United States — 272 open to participants now, 369 under way, 16 of them phase 3. Hypertension · United States.

Enrollment
487th of 1,779
300 · median 100
Started
2019
with 82 others
Phase 3
202 of 2,031
9 open now
Primary completion
2023-12
later than 5 of 367 live
Registered
1,068th of 2,031
by date

Among the 2,031 studies in Hypertension with a site in United States, this one is the 487th largest by enrollment of the 1,779 interventional ones that give a count, is one of 83 that started in 2019, is one of 202 in phase 3, reaches primary completion later than 5 of the 367 other live ones, and was the 1,068th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 909 are open to participants now.

Browse Hypertension studies →

Open to participants now

272 of the 2,031 studies in Hypertension with a site in United States are open now. Recruiting first, the newest first:

267 more — sign in →

All 272 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 558 Hypertension studies recruiting now, 265 (47%) set no upper age limit and 197 (35%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 2,031 studies in Hypertension with a site in United States, or all of them as a file.
02

Study summary

The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation - no alcohol infusion). Subjects will be randomized in a 1:1 fashion to treatment versus sham control via central randomization.

Read the detailed description

The TARGET BP I Trial is a randomized, blinded, multi-center, international, sham-procedure controlled trial, comparing renal denervation performed with the Peregrine System Kit in the treatment group to the sham control group (without renal denervation - no alcohol infusion). Subjects will be randomized in a 1:1 fashion to treatment versus sham control via central randomization.

The TARGET BP I clinical trial uses a percutaneous catheter to deliver very small amounts of alcohol (neurolytic agent). The patient population for this trial is comparable to those used in other renal denervation studies, but also incorporates lessons learned from recent trials of renal denervation. This is to enable the study of an optimized patient population who stands to benefit from the intervention, in a manner that reduces possible study bias.

This trial is intended to evaluate the safety and efficacy of the Peregrine Catheter when used to deliver a 0.6 mL volume of alcohol to the perivascular area of the respective renal arteries while patients are adequately managed with oral antihypertensive medications.

03

Conditions studied

  • Hypertension

Browse trials for

Keywords

  • Renal Denervation
  • Alcohol
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Has 3 office blood pressure measurements with a mean office systolic blood pressure (SBP) of ≥150 mmHg and ≤180 mmHg, AND a mean office diastolic blood pressure (DBP) of ≥90 mmHg when receiving 2 to 5 antihypertensive medications.
  2. Has a mean 24-hour ambulatory SBP of ≥135 mmHg and ≤170 mmHg with ≥70% valid readings

Exclusion criteria

Exclusion Criteria:

  1. Subject has renal artery anatomy abnormalities.
  2. Subject has an estimated (eGFR) of ≤45 mL/min/1.73 m2, based on the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation; or is on chronic renal replacement therapy.
  3. Subject has documented sleep apnea.
  4. Subject has any of the following conditions: severe cardiac valve stenosis, heart failure ( [NYHA] Class III or IV), chronic atrial fibrillation, and known primary pulmonary hypertension (>60 mmHg pulmonary artery or right ventricular systolic pressure).
  5. Subject is pregnant or lactating at the time of enrollment or planning to become pregnant during the trial time period (female subjects only).
  6. Subject is being treated chronically (e.g. daily use) with NSAIDs, medications, or immunosuppressive doses of . Aspirin therapy and nasal pulmonary inhalants are allowed.
  7. Subject has a history of myocardial infarction, unstable angina pectoris, or stroke/ within 6 months prior to the planned procedure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
300 participants (actual)

Study arms

  • Experimental
    Treated with Peregrine System Kit

    The experimental group will receive an infusion of Dehydrated Alcohol Injection, USP into the perivascular space of the renal arteries with the Peregrine Catheter. A total of 0.6mL of the alcohol will be delivered to the perivascular space of each renal artery. The drug will only be delivered once to each renal artery during the treatment procedure.

    Drug: Dehydrated alcohol

  • Sham comparator
    Renal Angiography Only (Sham Procedure)

    The sham control group will only have diagnostic renal angiography performed. There will be no insertion of the Peregrine Catheter and no alcohol infusion (i.e. no renal denervation).

    Device: Peregrine System Kit (Sham Procedure)

Interventions

  • Dehydrated Alcohol Injection, USP is used in the study.

    Also known as: Ethanol

  • DevicePeregrine System Kit (Sham Procedure)

    Pre-procedural diagnostic renal angiography only, performed for confirmation of anatomical eligibility prior to randomization

06

What researchers measure

Primary outcomes

  1. Change in mean systolic ABPM

    The change in mean 24-hour ambulatory SBP from baseline to 3 months post-procedure

    Time frame: 3 months

Secondary outcomes

  1. Proportion of subjects with major adverse events

    Major Adverse Events as defined in the clinical protocol

    Time frame: 30 days

  2. Major Adverse Events

    Major Adverse Events as defined in the clinical protocol

    Time frame: 3, 6, and 12 months and 2 and 3 years

  3. Decrease in eGFR > 25%

    Decrease in eGFR \> 25% at 3 and 6 months

    Time frame: 3 and 6 months

  4. Changes in eGFR

    Changes in eGFR at 3 and 6 months

    Time frame: 3 and 6 months

  5. Adverse event rate

    Adverse event rate at procedure, discharge, and at all follow-up visits

    Time frame: Procedure date, discharge date (an average of 1 day), 5-day, 4 weeks, 8 weeks, 3 months, 4 months, 5 months, 6 months, 1 year, 2 years and 3 years

  6. Device success

    Device success, defined as successful introduction of the catheter, navigation to the treatment site, deployment of the needles, and infusion of the alcohol to the intended area via the Peregrine Catheter as intended for use

    Time frame: Procedure date (day 0)

  7. Procedure success

    Procedure success defined as device success and freedom from serious adverse events related to the product or the procedure, during the procedure and prior to hospital discharge from the index procedure.

    Time frame: Hospital discharge date (an average of 1 day)

  8. Change of office systolic blood pressure

    Change of office systolic blood pressure from baseline to 8 weeks

    Time frame: 8 weeks

  9. Change of diastolic office blood pressure

    Change of diastolic office blood pressure from baseline to 3 and 6 months

    Time frame: 3 and 6 months

  10. Change of 24-hour mean diastolic ABPM

    Change of 24-hour mean diastolic ABPM from baseline to 3 and 6 months

    Time frame: 3 and 6 months

  11. Change of 24-hour mean systolic ABPM

    Change of 24-hour mean systolic ABPM from baseline to 6 months

    Time frame: 6 months

  12. Changes in antihypertensive regimen

    Changes in antihypertensive regimen from procedure to 3 months post-procedure

    Time frame: 3 months

  13. ABPM responders (5 mmHg)

    ABPM Responders, defined as the proportion of subjects with a drop of ≥5 mmHg in 24-hour ambulatory SBP at 3 months compared with baseline.

    Time frame: 3 months

  14. Office BP responders (10 mmHg)

    Office BP Responders, defined as the proportion of subjects with a drop of ≥10 mmHg in office SBP at 3 months compared with baseline.

    Time frame: 3 months

  15. Change in mean office SBP

    Change in mean office SBP from baseline to 6 months post-procedure

    Time frame: 6 months

  16. Change in mean daytime ambulatory SBP

    Change in mean daytime ambulatory SBP from baseline to 3 months post procedure.

    Time frame: 3 months

  17. Change in mean daytime ambulatory SBP

    Change in mean daytime ambulatory SBP from baseline to 6 months post procedure.

    Time frame: 6 months

  18. Change in mean daytime ambulatory DBP

    Change in mean daytime ambulatory DBP from baseline to 3 months and then 6 months post procedure.

    Time frame: 3 and 6 months

  19. Changes (decreases or increases) in antihypertensive medication regimen from 3 months to 6 months post-procedure

    Changes (decreases or increases) in antihypertensive medication regimen from 3 months to 6 months post-procedure (titrated according to standardized formula to maintain a target office SBP of \< 140 mmHg and ≥ 90 mmHg).

    Time frame: 3 and 6 months

  20. Changes (decreases or increases) in antihypertensive medication regimen from procedure to 6 months post-procedure

    Changes (decreases or increases) in antihypertensive medication regimen from procedure to 6 months post-procedure (titrated according to standardized formula to maintain a target office SBP of \<140 mmHg and ≥90 mmHg)

    Time frame: 6 months

  21. Change in mean nighttime ambulatory SBP

    Change in mean nighttime ambulatory SBP from baseline to 3 months and then 6 months post procedure.

    Time frame: 3 and 6 months

  22. Change in mean nighttime ambulatory DBP

    Change in mean nighttime ambulatory DBP from baseline to 3 months and then 6 months post procedure.

    Time frame: 3 and 6 months

  23. Reduction of office SBP and DBP to normal

    Reduction of office SBP and DBP to normal (\<140/90 mmHg) at 3, 6 and 12 months as compared to baseline.

    Time frame: 3, 6, and 12 months

07

Study locations

5 sites
08

References and documents

Publications

  • Bertog S, Sharma A, Mahfoud F, Pathak A, Schmieder RE, Sievert K, Papademetriou V, Weber MA, Haratani N, Lobo MD, Saxena M, Kandzari DE, Fischell TA, Sievert H. Alcohol-Mediated Renal Sympathetic Neurolysis for the Treatment of Hypertension: The Peregrine Infusion Catheter. Cardiovasc Revasc Med. 2021 Mar;24:77-86. doi: 10.1016/j.carrev.2020.09.003. Epub 2020 Sep 7. PubMed 32958438 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2019 (actual). Primary completion is estimated for Dec 2023, 53 months after the start.

Of 95 industry-sponsored phase 3 interventional studies under Hypertension, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 29. This study's planned 53 months is above that.

Counting every sponsor, half of 141 studies reached it within 21 months; a quarter within 12 and three quarters within 42.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2016
First posted
Sep 22, 2016
StartActual
Jul 22, 2019
Primary completionEst.
Dec 2023
CompletionEst.
May 2026
Last update
Oct 3, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 3, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02910414
Lead sponsor
Ablative Solutions, Inc.
Responsible party
Sponsor
First posted
Sep 22, 2016
Start date
Jul 22, 2019
Primary completion
Dec 2023 (estimated)
Completion
May 2026 (estimated)
Last update
Oct 3, 2023

Study contacts

David Kandzari, MD
principal investigator · Piedmont Heart Institute
Michael Weber, MD
principal investigator · SUNY Downstate Medical
Atul Pathak, MD
principal investigator · Clinique Pasteur
Felix Mahfoud, MD
principal investigator · Klinik fur Innere Medizin III

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ethanol

Start the discussion